COVID-19 and phosphodiesterase enzyme type 5 inhibitors

COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully develope...

Full description

Saved in:
Bibliographic Details
Published inThe journal of microscopy & ultrastructure Vol. 8; no. 4; pp. 141 - 145
Main Authors Al-Kuraishy, Hayder, Al-Gareeb, Ali, Al-Niemi, Marwa, Al-Buhadily, Ali, Al-Harchan, Nasser, Lugnier, Claire
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer India Pvt. Ltd 01.10.2020
Medknow Publications and Media Pvt. Ltd
Wolters Kluwer - Medknow
Subjects
Cilostazol
COVID-19
Lung diseases
Pulmonary hypertension
Review
COVID-19
Acute lung injury
nucleotide phosphodiesterase enzyme
Online AccessGet full text

Cover

More Information
Summary:COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension; interestingly, more recently, it was shown that PDE5Is might be also anti-inflammatory. Therefore, it would be of interest to question about the use of PDE5Is to overcome the COVID-19 storm, as much as PDE5 is mainly present in the lung tissues and vessels.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2213-879X
2213-8803
2213-8803
DOI:10.4103/JMAU.JMAU_63_20